NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2023 Earnings Call May 16, 2023 8:30 AM ET

Company Participants

Suzanne Messere - Investor Relations, Stern

Stephen Willard - Chief Executive Officer and Director

Seth Van Voorhees - Chief Financial Officer

Jonathan C. Javitt - Chief Scientist and Director

Conference Call Participants

Edward Woo - Ascendiant Capital Markets LLC

Jason Kolbert - Dawson James Securities

Operator

Good day, everyone, and welcome to NRx Pharmaceuticals’ First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please note, this event is being recorded.

I would now like to turn the conference over to Suzanne Messere with Stern, Investor Relations. Please go ahead.

Suzanne Messere

Thank you, Vashnavi. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof and the Company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release issued earlier today and in the Company's Form 10-K, which was re-filed on May 1, which may be accessed from the Investors page of the NRx Pharmaceuticals Inc. website.

Joining me on today's from NRx Pharmaceuticals are Stephen Willard, Chief Executive Officer and Seth Van Voorhees, Chief Financial Officer and Treasurer. Stephen, will provide a summary of the Company's progress. Seth, will review the Company's financial results and then, Stephen will review upcoming milestone before making closing comments.

Following their prepared remarks, Stephen and Seth will be joined by Jonathan Javitt, the Company's Chief Scientist and Matthew Duffy, the Company's Chief Business Officer to address your questions.

I will now turn the call over to Stephen.

Stephen Willard

Thank you, Suzanne. Good morning everyone and thank you for joining us to discuss our continued success, as we advance our pipeline of innovative therapeutics for patients facing psychiatric disorders with great unmet need, including treatment resistant suicidal bipolar depression, post-traumatic stress disorder and potentially chronic pain related to depression.